Repositioning Candidate Details
| Candidate ID: | R0911 |
| Source ID: | DB05983 |
| Source Type: | investigational |
| Compound Type: | small molecule |
| Compound Name: | Bardoxolone methyl |
| Synonyms: | Bardoxolone methyl |
| Molecular Formula: | C32H43NO4 |
| SMILES: | COC(=O)[C@]12CCC(C)(C)C[C@H]1[C@H]1C(=O)C=C3[C@@]4(C)C=C(C#N)C(=O)C(C)(C)[C@@H]4CC[C@@]3(C)[C@]1(C)CC2 |
| Structure: |
|
| DrugBank Description: | -- |
| CAS Number: | 218600-53-4 |
| Molecular Weight: | 505.699 |
| DrugBank Indication: | Investigated for use/treatment in lymphoma (unspecified), multiple myeloma, and solid tumors. |
| DrugBank Pharmacology: | -- |
| DrugBank MoA: | RTA 402 inhibits the activity of nuclear factor kappa-B (NF-kB) activated by tumor necrosis factor (TNF) and other inflammatory agents in a variety of cancer cells. It is a novel targeted cancer therapy with a unique mechanism of action. It exploits fundamental physiological differences between cancerous and noncancerous cells by modulating oxidative stress response pathways. As a result, the drug is toxic to cancer cells but induces protective antioxidant and anti-inflammatory responses in normal cells. |
| Targets: | NF-kappa-B inhibitor alpha |
| Inclusion Criteria: | Therapeutic strategy associated |
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs | |
|---|---|---|---|---|---|
| S04 | Anti-oxidative stress | oxidative stress | α-tocopherol: antioxidant | Vitamin E | Details |
| S05 | Anti-inflammatory | inflammatory | Bile acid; TNF-a inhibitor; Dual PPAR-α and -δ agonists; Toll-Like Receptor; (TLR)-4 antagonist; Caspase inhibitor; ASK-1 inhibitor | Ursodeoxycholic Acid; Pentoxifylline; Elafibranor; JKB-121; Emricasan; Selonsertib; | Details |
| Diseases ID | DO ID | Disease Name | Definition | Class |
|---|